Literature DB >> 30342166

Tumor necrosis factor-α inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: A multicenter retrospective study.

Laurie Rousset1, Adèle de Masson1, Edouard Begon2, Axel Villani3, Maxime Battistella4, Michel Rybojad1, Marie Jachiet1, Martine Bagot1, Jean-David Bouaziz1, Clémence Lepelletier5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30342166     DOI： 10.1016/j.jaad.2018.10.006

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  3 in total

1.  Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Final analysis of a 52-week phase 3 open-label study.

Authors:  Kenshi Yamasaki; Keiichi Yamanaka; Yiwei Zhao; Shunsuke Iwano; Keiko Takei; Koji Suzuki; Toshiyuki Yamamoto
Journal:  J Dermatol       Date:  2022-03-03       Impact factor: 3.468

Review 2.  Informed consent and biological agents in rheumatology and internal medicine.

Authors:  Gabriele Mandarelli; Florenzo Iannone; Stefano Ferracuti; Ignazio Grattagliano; Marcello Benevento; Biagio Solarino; Davide Ferorelli; Roberto Catanesi
Journal:  Eur J Clin Invest       Date:  2022-05-18       Impact factor: 5.722

3.  Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty-six-week phase 3 open-label study.

Authors:  Kenshi Yamasaki; Keiichi Yamanaka; Yiwei Zhao; Shunsuke Iwano; Keiko Takei; Koji Suzuki; Toshiyuki Yamamoto
Journal:  J Dermatol       Date:  2020-08-17       Impact factor: 4.005
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.